Printer Friendly

LEADING WOMEN'S HEALTH CARE PRACTITIONER JOINS COLUMBIA LABORATORIES' BOARD OF DIRECTORS

 HOLLYWOOD, Fla., Nov. 24 ~PRNewswire~ -- Columbia Laboratories, Inc. (AMEX: COB) announced Friday that one of the country's most respected physicians in the area of women's health care, Dr. Lila E. Nachtigall, has been appointed to the board of directors for the Florida-based pharmaceutical company specializing in women's health care products.
 Dr. Nachtigall is associate professor of Obstetrics and Gynecology at New York University School of Medicine. In addition, she is clinic coordinator of GYN-Endocrine Clinic at Bellevue Hospital Center, co- director of the GYN-Endocrine Program, and director of the Women's Wellness Division at New York University Medical Center. Her major research interest are in estrogen replacement in pre- and post- menopausal women. She lectures extensively on women's health issues and has published several articles related to the subject.
 "With the addition of Dr. Nachtigall to our board of directors, Columbia Labs has gained the expertise of one of the leading physicians in women's health care services. Her participation and experience will assist the company as we strive to be the leader in women's health care products worldwide," said Norman M. Meier, president and chief executive officer of Columbia.
 Columbia Laboratories, Inc. is a U.S.-based multinational pharmaceutical company, established in 1987, dedicated primarily to developing women's health care products based on its patented bioadhesive drug delivery system.
 -0- 11~24~92
 ~CONTACT: Margaret Roell, chief financial officer of Columbia Laboratories, Inc., 305-964-6666, or Pamela R. Julius of Howard J. Rubenstein Associates, 212-489-6900, for Columbia Laboratories, Inc.~
 (COB)


CO: Columbia Laboratories, Inc. ST: Florida IN: MTC SU: PER

GK -- NY001B -- 1175 11~24~92 15:17 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 24, 1992
Words:267
Previous Article:APPLEBEE'S DECLARES ANNUAL DIVIDEND
Next Article:NUI CORPORATION REPORTS IMPROVED RESULTS FOR FISCAL YEAR; $1.68 PER SHARE VERSUS $0.55
Topics:


Related Articles
COLUMBIA LABORATORIES SIGNS LETTER OF INTENT TO LICENSE AND SUPPLY REPLENS AND OTHER WOMEN'S OTC HEALTH CARE PRODUCTS
TEVA PHARMACEUTICALS TO MARKET COLUMBIA LABORATORIES' WOMEN'S HEALTH CARE PRODUCTS IN ISRAEL
LEADING WOMEN'S HEALTH CARE PRACTITIONER JOINS COLUMBIA LABORATORIES' BOARD OF DIRECTORS
ROBERT LEVY, M.D. JOINS GENETICS INSTITUTE BOARD; BERNARD CANAVAN, M.D. RESIGNS
FDA Decision Recognizes Complexity of Premarin(R) (conjugated estrogens tablets, USP)
Wyeth-Ayerst Announces Membership of Cardiovascular Assessment Expert Panel
Columbia Laboratories Moves to NASDAQ National Market Under New Symbol CBRX.
Columbia Laboratories Grants Approval to Allow Shareholder To Increase Position to 19.9%.
Columbia Laboratories Appoints George W. Creasy, M.D. to Vice President, Clinical Research, and Paul B. Schwartz to Executive Director, Licensing &...
Robert S. Mills Promoted to Sr. Vice President and Chief Operating Officer Of Columbia Laboratories.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters